Skip to main content
Publications
Diez-Campelo M, Yucel A, Goyal RK , Parikh RC , Esterberg E , Jimenez M , Sluga-O'Callaghan M , Miteva D, Xiao H, Germing U. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe . Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228
Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL , Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer . Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573
Webb S, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM , Signorovitch JE, McLeod L , Maldonado M, Zgliczylski W, De Block C, Portocarrero-Ortiz L, Gadelha MR. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease . Eur J Endocrinol. 2014 Jul;171(1):89-98. doi: 10.1530/EJE-13-1013
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043